JAVMA study details atypical radiographic changes with Librela

A new JAVMA report is sharpening attention on a possible musculoskeletal safety signal for bedinvetmab (Librela), Zoetis’ anti-nerve growth factor monoclonal antibody for canine osteoarthritis pain. The paper, published online August 31, 2026, describes atypical radiographic changes in dogs treated with the drug, based on cases drawn from the company’s global pharmacovigilance database. Among 319 potential musculoskeletal adverse-event cases identified from November 2020 through December 2025, 186 met inclusion criteria and showed imaging findings the authors said could not be explained by expected osteoarthritis progression or other recognized orthopedic disease patterns. (vetree.app)

The study arrives after nearly two years of escalating scrutiny around Librela’s post-market safety profile. FDA approved the drug on May 5, 2023, for control of pain associated with osteoarthritis in dogs. In a standard adverse-event pharmacovigilance review covering approval through March 31, 2024, the agency said its database contained 3,674 Librela-associated cases as of April 18, 2024, including 3,637 in dogs, and noted that on July 1, 2024, CVM recommended labeling revisions based on new safety information acquired after approval. In December 2024, FDA sent a Dear Veterinarian letter saying it had reviewed reports that included ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, and polydipsia, with death, including euthanasia, reported in some cases. (fda.gov)

What’s new here is the focus on imaging-defined orthopedic change rather than the neurologic and urinary signals that have dominated much of the public discussion. According to the JAVMA summary, abnormal periarticular bone remodeling was the most frequently observed finding, and the elbow and tarsus were the most commonly affected joints. The changes could be unilateral or bilateral, progressive over time, and present in more than one joint in the same dog. The report also found that 63% of included cases involved concurrent NSAID administration, and 25% reflected off-label bedinvetmab use. Those details matter because FDA’s product review and current U.S. labeling both note that safe use of anti-NGF monoclonal antibodies with concurrent NSAIDs has not been established in dogs. (vetree.app)

The broader scientific backdrop is also evolving. A Frontiers in Veterinary Science paper published in August 2026 proposed that multisystem adverse events associated with canine anti-NGF therapies, including bedinvetmab and izenivetmab, may reflect “neurotrophic withdrawal” caused by systemic NGF sequestration, potentially affecting joint protection, autonomic regulation, and neuronal maintenance, especially in geriatric dogs. That hypothesis does not prove causation for the radiographic findings in the new JAVMA series, but it shows that researchers are trying to connect disparate post-marketing signals through a biologically coherent mechanism. (frontiersin.org)

Regulators outside the U.S. are also watching closely. In the UK, the Veterinary Medicines Directorate said in 2026 that it had completed an in-depth safety assessment of Librela and still considered the product’s overall benefit-risk balance positive, while encouraging detailed adverse-event reporting, including imaging findings. Separately, a UK government disclosure described emerging evidence of severe and rapidly progressive arthritic changes associated with anti-NGF monoclonal antibodies, including severe osteophytosis, periosteal reactions, bone erosion, instability, subluxation, joint collapse, osteolysis, and destructive arthropathy beyond expected osteoarthritis progression. (gov.uk)

Zoetis has consistently defended Librela’s overall safety and efficacy while acknowledging the need for updated risk communication. In December 2024, the company said FDA’s communication aligned with its own ongoing monitoring and that it was discussing label updates with the agency. By February 2025, those updates had been reflected in the U.S. label, including a post-approval adverse-event section, stronger instructions to review a client information sheet before each injection, and added language advising veterinarians to discuss potential adverse reactions with pet parents before treatment. The current label lists post-approval reports including neurologic, urinary, gastrointestinal, and musculoskeletal events, and notes that serious adverse reactions can result in death or euthanasia. (news.zoetis.com)

Why it matters: For veterinary professionals, the practical takeaway is less about abandoning a commonly used OA analgesic and more about tightening clinical discipline around it. Librela remains approved and widely used, but this case series suggests that if a dog on bedinvetmab develops new, shifting, or unexpectedly severe lameness, clinicians may need to think beyond “progressing OA” and consider repeat radiographs, review of concomitant NSAID exposure, and whether the original diagnosis still fits. It also reinforces the importance of documenting baseline orthopedic status, setting expectations with pet parents that pain relief does not slow arthritis progression, and reporting adverse events with as much detail as possible, including treatment history, lot number, concurrent medications, and imaging findings. (fda.gov)

What to watch: The next phase will likely be prospective work: independent imaging studies, clearer phenotype definitions for these atypical changes, and possible refinements to guidance on case selection, off-label use, and NSAID co-administration. Whether regulators move toward additional labeling changes will depend on how convincingly future studies separate drug-associated patterns from the background noise of advanced orthopedic disease in an older canine population. (fda.gov)